Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 150 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Cidara Therapeutics Inc | CDTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 13.00 | 04:01:31 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 13.00 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 7 | 150 | - | 10.004 - 29.60 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 04:04:51 | 97 | $ 12.75 | USD |
Cidara Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.18B | 90.43M | - | 64.29M | -29.8M | -0.33 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Cidara Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CDTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 14.10 | 14.96 | 10.004 | 10.80 | 1,405,907 | -1.10 | -7.80% |
| 1 Month | 16.20 | 24.40 | 10.004 | 16.92 | 1,200,095 | -3.20 | -19.75% |
| 3 Months | 13.198 | 24.40 | 10.004 | 15.84 | 744,906 | -0.198 | -1.50% |
| 6 Months | 17.00 | 24.40 | 10.004 | 15.58 | 681,524 | -4.00 | -23.53% |
| 1 Year | 20.60 | 29.60 | 10.004 | 18.74 | 673,530 | -7.60 | -36.89% |
| 3 Years | 44.20 | 47.80 | 8.00 | 24.59 | 806,250 | -31.20 | -70.59% |
| 5 Years | 45.60 | 89.00 | 8.00 | 31.54 | 637,543 | -32.60 | -71.49% |
Cidara Therapeutics Description
| Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. |
